| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 10/17/2001 | EP1144614A2 33 human secreted proteins |
| 10/17/2001 | EP1144605A2 Dimethylarginine dimethylaminohydrolases |
| 10/17/2001 | EP1144595A2 Platform for the differentiation of cells |
| 10/17/2001 | EP1144458A1 Substance for reduction of cholesterol as well as lipids content |
| 10/17/2001 | EP1144454A2 Modified peptides as therapeutic agents |
| 10/17/2001 | EP1144443A2 Human membrane transport proteins |
| 10/17/2001 | EP1144435A2 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 10/17/2001 | EP1144425A1 Derivatives of monosaccharides as cell adhesion inhibitors |
| 10/17/2001 | EP1144409A2 Phenyl urea and phenyl thiourea derivatives |
| 10/17/2001 | EP1144405A1 Triazole compounds with dopamine-d3-receptor affinity |
| 10/17/2001 | EP1144402A2 Substituted oximes and hydrazones as neurokinin antagonists |
| 10/17/2001 | EP1144395A1 2-amino-benzoxazinone derivatives for the treatment of obesity |
| 10/17/2001 | EP1144394A1 1-heterocycle substituted diarylamines |
| 10/17/2001 | EP1144393A2 Heterocyclic derivatives and their use as integrin inhibitor |
| 10/17/2001 | EP1144390A2 Kinase inhibitors |
| 10/17/2001 | EP1144389A1 Crystalline bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoicacid]calcium salt |
| 10/17/2001 | EP1144388A1 Acyl derivatives which treat vla-4 related disorders |
| 10/17/2001 | EP1144387A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| 10/17/2001 | EP1144385A1 Benzoheterocycles and their use as mek inhibitors |
| 10/17/2001 | EP1144384A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 10/17/2001 | EP1144377A1 Oxetanone derivatives |
| 10/17/2001 | EP1144372A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| 10/17/2001 | EP1144371A1 Benzenesulphonamide derivatives and their use as mek inhibitors |
| 10/17/2001 | EP1144370A2 Thyroid receptor ligands |
| 10/17/2001 | EP1144368A2 Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
| 10/17/2001 | EP1144364A2 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 10/17/2001 | EP1143999A2 Lipoprotein complexes and compositions containing them |
| 10/17/2001 | EP1143988A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of type 2 diabetes, the metabolic syndrome and associated cardiovascular diseases |
| 10/17/2001 | EP1143984A1 Egg anti-inflammatory composition and method of treating and preventing inflammation |
| 10/17/2001 | EP1143979A1 Use of estrogens and delta-gonadien-21-ol-3,20-diones for treating insulin dependent and non-insulin dependent diabetes |
| 10/17/2001 | EP1143977A1 2-oxy-benzoxazinone derivatives for the treatment of obesity |
| 10/17/2001 | EP1143974A1 Pharmaceutical compositions for alleviating discomfort |
| 10/17/2001 | EP1143965A1 Carbocyclic potassium channel inhibitors |
| 10/17/2001 | EP1143964A1 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission |
| 10/17/2001 | EP1143955A2 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
| 10/17/2001 | EP1143949A2 19-nor-vitamin d3 compounds with calcemic activity |
| 10/17/2001 | EP1143948A2 Liver-selective glucocorticoid antagonist for treating diabetes |
| 10/17/2001 | EP1143944A2 Use of arylalkanoylpyridazines |
| 10/17/2001 | EP1143932A1 Transnasal transport/immunisation with highly adaptable carriers |
| 10/17/2001 | EP1143931A1 Pulmonary drug delivery |
| 10/17/2001 | EP0999841B1 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine |
| 10/17/2001 | CN1318063A Process for obtaiing HMG-CoA reductase inhibitors of high purity |
| 10/17/2001 | CN1318058A 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as CRTP inhibitors |
| 10/17/2001 | CN1318057A 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinoliines as CETP inhibitors |
| 10/17/2001 | CN1318056A Pyridinum derivatives for management of aging-related and diabetic vascular complications, process for their prepn. and therepeutic uses thereof |
| 10/17/2001 | CN1317972A Compsn contg. rutin and quercetin for preventing or treating elevated blood lipid level-related diseases |
| 10/17/2001 | CN1317970A Method for treating atherosclerosis empolying ap2 inhibitor and combination |
| 10/17/2001 | CN1317968A 2-bustituted-1-piperidyl benzimidazole compounds as or/1-receptor agonists |
| 10/17/2001 | CN1317967A Protein formulations |
| 10/17/2001 | CN1317961A Compsn. contg. cinnamic acid derivatives for preventing or treating elevated blood lipid level-releated diseases |
| 10/17/2001 | CN1317960A Pharmaceutical compsn. comprising D-i(chiro)-inositol for improving insulin sensitivity and glucose metabolism |
| 10/17/2001 | CN1317938A Compsn. contg. neohesperidin dihydrochalcone for preventing or treating elevated blood lipid and glucose level-reated diseases |
| 10/17/2001 | CN1317937A Compsn. containing natural phenolic compound for preventing or treating elevated blood liquid level-related diseases |
| 10/17/2001 | CN1317340A Health food for diabetics |
| 10/17/2001 | CN1317337A Rehmannia root extract and its preparing process and application |
| 10/17/2001 | CN1317310A Method of preparing solid state creatine dosage and creatine dosage by same |
| 10/17/2001 | CN1073102C New 4-(1-piperazinyl) benzoic acid derivatives, process for preparing them and their therapeutic applications |
| 10/17/2001 | CN1072958C Pancreas-recovering thirst-relieving and blood sugar reducing powder, and preparing method thereof |
| 10/17/2001 | CN1072946C Diabetes treating medicine |
| 10/17/2001 | CN1072908C Food additive benefiting patients of diabetics, coronary heart disease and tumor |
| 10/17/2001 | CA2343843A1 Therapeutic light source and method |
| 10/16/2001 | US6303661 Orally administering inhibitor of dipeptidyl peptidase (dp iv) or of dipeptidyl peptidase iv-like activity |
| 10/16/2001 | US6303653 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| 10/16/2001 | US6303640 Administering oxazole or thiazole derivative compound for reducing side effects of diabetic therapy |
| 10/16/2001 | US6303639 Propanolamine derivatives substituted by heterocyclic radicals, processes for their preparation, pharmaceuticals comprising these compounds and their use |
| 10/16/2001 | US6303637 For therapy of autoimmune disease, prophylaxis of resistance to transplantation or transplantation rejection of organs or tissues; suppressing immune system |
| 10/16/2001 | US6303627 For therapy of physiological and psychological disorders |
| 10/16/2001 | US6303614 Tetrahydro gamma-carbolines |
| 10/16/2001 | US6303586 Ingesting therapeutically effective amount of stabilized rice bran solubilized fraction, wherein said stabilized rice bran solubilized fraction is free of stabilized rice bran insolubilized fraction to reducing serum glucose in mammal |
| 10/16/2001 | US6303580 Cyclitol Containing carbohydrates from human tissue which regulate lipogenic activity |
| 10/16/2001 | US6303333 Expression vector which codes polypeptides for the diagnosis and treatment of cancer, dietetics, inflammation, cardiovascular disorders, crohn's diseases, neuropathies and immune defects |
| 10/16/2001 | US6303321 Methods for diagnosing sepsis |
| 10/16/2001 | US6303314 T-cell receptor Vβ-Dβ-Jβ sequence and methods for its detection |
| 10/16/2001 | US6303167 Mixing silica and liquid mixed tocopherol to produce dry free-flowing powders |
| 10/16/2001 | US6303146 Solid oral dosage form comprising a combination of metformin and glibenclamide |
| 10/16/2001 | US6303127 Treatment of disease states |
| 10/16/2001 | US6303121 Method of using human receptor protein 4-1BB |
| 10/16/2001 | CA2210988C A low phosphorus animal feed containing 1.alpha.-hydroxylated vitamin d compounds |
| 10/16/2001 | CA2181156C Macroencapsulated secretory cells |
| 10/16/2001 | CA2144104C Peptide derivatives having binding activity to modified low density lipoprotein |
| 10/16/2001 | CA2096350C Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth) |
| 10/16/2001 | CA2035967C Oxetanones |
| 10/16/2001 | CA2025301C New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase |
| 10/16/2001 | CA2001774C Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
| 10/13/2001 | CA2343850A1 Synergistic effect of a sulfonylurea and/or non-sulfonylurea k+ atp channel blocker, and a phosphodiesterase 3 type inhibitor |
| 10/11/2001 | WO2001075170A1 A functional assay of high-density lipoprotein |
| 10/11/2001 | WO2001075168A1 Control of a gene induced by oxidized lipids in human artery wall cells |
| 10/11/2001 | WO2001075135A1 Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders |
| 10/11/2001 | WO2001075108A1 Human ion channel protein and polynucleotides encoding the same |
| 10/11/2001 | WO2001074904A2 G-protein coupled receptors and nucleic acids encoding same |
| 10/11/2001 | WO2001074903A2 CD20/IgE-RECEPTOR LIKE MOLECULES AND USES THEREOF |
| 10/11/2001 | WO2001074896A1 Human polynucleotides, polypeptides, and antibodies |
| 10/11/2001 | WO2001074844A2 Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity |
| 10/11/2001 | WO2001074835A1 O-glucosylated benzamide sglt2 inhibitors and method |
| 10/11/2001 | WO2001074834A1 O-aryl glucoside sglt2 inhibitors and method |
| 10/11/2001 | WO2001074820A1 Novel derivatives and analogues of galanthamin |
| 10/11/2001 | WO2001074775A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands |
| 10/11/2001 | WO2001074771A1 Pyrrole-2,5-dione derivatives for the treatment of diabetes |
| 10/11/2001 | WO2001074766A1 2-alkylidene-19-nor-vitamin d compounds and their therapeutic uses |
| 10/11/2001 | WO2001074506A1 Extrusion die |